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755LV ejection fraction, which in itself may be related
to reduced activity levels. Further, our data ac-
count for activity levels well outside the peri-
implantation window, which mitigates the impact of
periprocedural complications on the relationship be-
tween activity time and mortality.
Our study is limited by the relatively small study
population. We did not include other pacing devices
with accelerometers as their algorithms for deter-
mining active time may differ from the 2 devices
included in this study. We elected not to include pa-
tients with deﬁbrillators so as to reduce the con-
founding effects of impaired cardiac function on
activity levels. Balanced against these limitations are
the quantitative nature of our data, the novelty of the
ﬁndings and their potential impact on the care of
patients post-pacemaker implantation.
Physical activity as measured by an implanted
accelerometer is correlated with mortality—those who
are less active have decreased survival independent
of other risk factors. Our ﬁndings support the notion
that care providers following patients with pace-
makers could use these readily available data for risk
stratiﬁcation, to encourage increased physical activ-
ity, and to follow patient compliance with physical
activity recommendations. Whether interventions to
decrease inactive time can impact survival needs to
be prospectively studied.Sudhi Tyagi, MD
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Syndrome as a Predictor
of Cardiovascular Disease
Between Childhood
and Adulthood
The Princeton Lipid Research Cohort StudyThe long-term ability of the metabolic syndrome
(MetS) to predict cardiovascular disease (CVD) has
been limited by the binary nature of traditional
MetS criteria and by discrepancies among African
Americans, who have low rates of MetS classiﬁcation
despite higher rates of death from CVD (1). We pre-
viously used conﬁrmatory factor analysis to formu-
late MetS severity z-scores for adolescents (2) and
adults (3) that place differential weights on the indi-
vidual MetS components to account for variation in
how MetS is manifest by sex and racial/ethnic group.
Our goal was to assess the ability of these scores to
determine long-term risk for CVD.
The Princeton Lipid Research Cohort Study fol-
lowed white and black (30.5%) individuals (55.5%
female) over 3 phases: 1) the LRC (Lipid Research
Clinic) (1973 to 1976) evaluated MetS measures on
students in grades 1 to 12 (4); 2) the PFS (Princeton
Follow-Up Study) (1998 to 2003) evaluated complete
MetS measures and reported CVD status on 629 LRC
participants (4); and 3) the PHU (Princeton Health
Update) (2010 to 2014) assessed CVD outcomes via
phone interviews and National Death Index query
on 354 cohort members. CVD was classiﬁed as self-
reported myocardial infarction, coronary artery
bypass, other heart surgery, coronary revasculariza-
tion procedure (angioplasty, stent placement), or
stroke. MetS severity z-scores were calculated from
each individual’s measures of body mass index
z-score (children/adolescents) or waist circumference
(adults), systolic blood pressure, fasting triglycerides,
and fasting glucose, based on equations speciﬁc to
sex and racial/ethnic subgroup from LRC and PFS
visits. Mean MetS z-scores were compared based on
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756participants’ CVD diagnosis by the PFS or PHU. Logis-
tic regression and receiver-operating characteristic
(ROC) curves were used to evaluate the ability of MetS
severity scores to predict future CVD.
MetS severity z-scores during childhood (LRC,
mean 12.9 years of age) were lowest among those
who never developed CVD, highest among those with
early CVD (PFS, mean 38.4 years of age) and inter-
mediate among those with later CVD (PHU, mean
49.6 years of age) (Figure 1). In predicting future
CVD, ROC curves revealed that childhood MetS
severity z-scores had areas under the curve of 0.91
and 0.65 by PFS and PHU, respectively, while MetS
z-scores at PFS had area under the curve of 0.84 for
subsequent CVD by PHU.
Using logistic regression, each 1.0 increase in
childhood MetS severity z-scores carried elevated
odds ratios of 9.8 and 2.4 for incident CVD by PFS and
PHU, respectively (p < 0.001 and p < 0.05). When
change in MetS severity z-score from LRC to PFS was
added to baseline LRC z-score in the model, this car-
ried a further elevated odds ratio of 3.4 for incident
CVD between PFS and PHU (p < 0.01).
The long-term health consequences of obesity—
including CVD—underscore the need for clinical toolsFIGURE 1 Mean MetS Severity Scores (Mean, 95% Conﬁdence
Interval) by Adult CVD Status
LRC Visit
(1973-1976)
PFS Visit
(1998-2003)
*#
*
*
1.  No CVD (n=321)
3.  CVD by PFS visit (n=5)
2.  CVD by PHU visit (2010-2014)(n=15)
Incident CVD
M
et
S 
Se
ve
rit
y 
Sc
or
e 
-1
0
1
2
3
Childhood (LRC [Lipid Research Clinic]) and adult (PFS [Princeton
Follow-Up Study]) scores for 3 groups: 1) disease-free
throughout; 2) early cardiovascular disease (CVD) (between LRC
and PFS); and 3) later incident CVD (between PFS and PHU
[Princeton Health Update]). Comparison with disease-free group:
*p < 0.001. Comparison with incident disease between PFS
and PHU: #p < 0.05. MetS ¼ metabolic syndrome.to assist in risk prediction to target at-risk individuals
for preventive therapy. We found that a sex- and
race/ethnicity-speciﬁc MetS severity z-score may
serve as such a tool in assisting disease prediction in
2 ways: 1) baseline MetS severity scores in childhood
and in mid-adulthood predicted later CVD diagnosis;
and 2) the change in score during the interval from
childhood to adulthood was associated with future
disease, even after adjustment for baseline scores.
In this sense, this score overcomes limitations of
traditional MetS criteria, which are based on in-
dividuals having abnormalities in $3 of the individual
MetS components and are thus unable to assess
for changes in MetS over time within an individual
(besides its presence/absence)—and are unable to
assess risk related to component values just below
the population-based cutoff.
This score is associated with risk for CVD and may
serve as a marker of the degree of the severity of
metabolic derangements behind MetS. Such a score—
potentially calculated automatically in an elec-
tronic health record system—could enable tracking
changes in a given individual’s MetS severity, both
to assess response to speciﬁc therapies and to
identify ominous increases in MetS severity as a
marker of risk and a trigger for further intervention.
Future research is needed to determine clinically
useful cutoffs of particularly elevated risk and
whether this score improves CVD risk prediction
above traditional criteria on a sex and race/ethnic
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Absence of Evidence or Evidence of AbsenceIn their recent perspective, Arbab-Zadeh and
Fuster explore the generally accepted concept that
atherothrombotic events result from the interaction
between systemic factors (inﬂammation and throm-
bosis) and local substrates (individual plaques).
Although this notion has appeared in the literature
for more than a decade, the authors emphasize the
importance of overall atherosclerotic plaque burden
rather than identiﬁcation and characterization of
vulnerable (or high-risk) plaque in cardiovascular
(CV) risk prediction.
Fundamentally, the authors accept that “plaque
ruptures and erosions are indeed responsible for
most culprit lesions in patients with acute events”
but express reservations about the feasibility of
vulnerable plaque diagnosis, given the prevalence of
subclinical plaque rupture events. However, several
points are worth considering when evaluating the
merits of the authors arguments:
1. Imaging studies associating vulnerable plaque with
future CV events have generally not accounted
for anatomic plaque burden as a confounder.TABLE 1 Study Types and Cardiovascular Event Predictor
Plaque Burden
First Author
(Ref. #) Population Events
Budoff et al. (1) N ¼ 25,252 asymptomatic
patients undergoing CAC
All-cause death: RR ¼
CAC >1,000 and R
CAC 400–699 (bot
Cho et al. (4) N ¼ 27,125 asymptomatic
patients undergoing CTA
and CAC
All-cause death: HR ¼
for CAC >400 (p ¼
HR ¼ 2.91 for mult
(p ¼ 0.001)
Criqui et al. (3) N ¼ 3,398 asymptomatic
cohort undergoing CAC
CVD: HR ¼1.68 per SD
in CAC volume (p <
*Remained signiﬁcant after adjusting for anatomic plaque burden (CAD >50% stenosis)
ACS¼ acute coronary syndrome(s); CAC ¼ coronary artery calcium; CAD ¼ coronary art
MACE ¼major adverse cardiac event(s); MRI ¼magnetic resonance imaging; OR ¼ odds r
VH ¼ virtual histology.Similarly, studies of anatomic plaque burden have
typically not adjusted for high-risk plaque features.
Given this, and that most imaging studies account
for similar CV and demographic risk factors, it is
instructive to compare the predictive value of
selected studies comparing anatomic burden to
vulnerable plaque (Table 1). Notably, the adjusted
risk estimates for death and/or major adverse car-
diac events (MACE) are generally comparable for
both plaque burden and plaque vulnerability char-
acteristics. The study by Budoff et al. (1) represents
the exception to this trend but was assessed in the
extreme upper tier of coronary artery calcium (CAC)
(>1,000), constituting <5% of the study population.
Importantly, lower CAC in their study was associ-
ated with a risk of clinical events comparable to
other studies at the same level of CAC.
The studies by Puchner et al. (2) and Criqui et al. (3)
(Table 1) are particularly interesting in that they
provide insight into the interplay between various
prognostic factors in coronary artery disease
(CAD): plaque burden and plaque vulnerability.
Evaluating patients with chest pain using coronary
computed tomography angiography (CTA), Puchner
et al. (2) observed that high-risk plaque (deﬁned as
at least 1 of the following: positive remodeling,
plaque with low Hounsﬁeld units [<30], napkin-
ring sign, spotty calcium) was predictive of acute
coronary syndromes after adjustment for plaque
burden (any coronary artery with a $50% or $70%
stenosis). Criqui et al. (3) found that CV risk was
inversely proportional to CAC density (i.e., vulner-
able plaque features) at any level of CAC volume
(i.e., plaque burden). These studies demonstrate
the incremental prognostic value of characterizing
features of individual plaque vulnerability in theVulnerable Plaque Features
First Author
(Ref. #) Population Events
9.36 for
R ¼ 5.78 for
h p < 0.0001)
Puchner et al. (2) N ¼ 472 patients
undergoing CTA
for chest evaluation
ACS*: OR ¼ 8.9 for
“high-risk” plaque
(p ¼ 0.006)
2.38 for death
0.014) and
ivessel CAD
Stone et al. (5) N ¼ 697 with ACS
undergoing
PCI þ IVUS
MACE: HR ¼ 3.35 for
VH-TCFA (p < 0.001)
and HR ¼ 5.03 PB >70%
(p < 0.001)
increase
0.001)
HR ¼ 0.71 per increase in
CAC density (p < 0.001)
.
ery disease; CTA ¼ coronary computed tomography angiography; HR ¼ hazard ratio; IVUS¼ intravascular ultrasound;
atio; PB ¼ plaque burden; PCI ¼ percutaneous coronary intervention; RR ¼ risk ratio; TCFA ¼ thin-cap ﬁbroatheroma;
